Provided is the use of selenite or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment or prevention of a non-tauopathy neurological disorder selected from the group consisting of stroke, cerebral ischaemia, dementia associated with stroke or cerebral ischaemia, dementia associated with HIV, disorders associated with excitotoxicity, epilepsy, seizures, schizophrenia, acute brain trauma (traumatic brain injury) and oxygen glucose deprivation.
